Cleft palate in HIV-exposed newborns of mothers on highly active antiretroviral therapy

Oral Surgery

Volumn 7, Issue S1, 2014, Pages 102-106

  Fasunla, A J ^a   Ogunbosi, B O ^a   Odaibo, G N ^a,b,c   Taiwo, B ^d   Nwaorgu, O G B ^a   Olaleye, D O ^a,b,c   Murphy, R L ^d   Adewole, I F ^a,b,c   Kanki, P ^e   Akinyinka, O O ^a,b,c  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b Medical Education Partnership In Nigeria   (Nigeria)

^c APIN PUBLIC HEALTH INITIATIVES   (Nigeria)

^d NORTHWESTERN UNIVERSITY   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cleft palate; Efavirenz; Highly active antiretroviral therapy (HAART); Human immunodeficiency virus (HIV); Nevirapine; Newborns

Indexed keywords

EID: 84919394141     PISSN: 17522471     EISSN: 1752248X     Source Type: Journal    
DOI: 10.1111/ors.12117     Document Type: Article

References (30)

1. Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther 2007;32:293-311.
2. Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007;(1):CD003510.
3. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. Available from URL: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/ [accessed 30 June 2013].
4. Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther 2004;2:671-684.
5. Jordan WC, Jefferson R, Yemofio F, Tolbert L, Conlon V, Carroll H etal. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. J Natl Med Assoc 2003;95:1152-1157.
6. Nightingale SL. From the food and drug administration. J Am Med Assoc 1998;280:1472.
7. Ford N, Calmy A, Mofenson L. Safety of Efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011;25:2301-2304.
8. Cartsos VM, Palaska PK, Zavras AI. Antiretroviral prophylaxis and risk of cleft lip and palate: preliminary signal detection in the food and drug administration's adverse events reporting system database. Cleft Palate Craniofac J 2012;49:118-121.
9. Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother 2007;8:851-871.
10. Fisher B, Rose NC, Carey JC. Principles and practice of teratology for the obstetrician. Clin Obstet Gynecol 2008;51:106-118.
11. Shanske AL. Bilateral oblique facial clefts and extremity anomaly in an infant after intrauterine Efavirenz exposure and review of its teratogenic risk. AIDS 2012;26:1775-1779.
12. Butali A, Adeyemo WL, Mossey PA etal. Prevalence of orofacial cleft in Nigeria. Cleft Palate Craniofac J 2013;51:320-325. http://dx.doi.org/10.1597/12-135.
13. Agbenorku P, Yore M, Danso KA, Turpin C. Incidence of orofacial clefts in Kumasi, Ghana. ISRN Plast Surg 2013;2013:280903. http://dx.doi.org/10.5402/2013/280903.
14. Murray JC. Gene/environment causes of cleft lip and/or palate. Clin Genet 2002;61:248-256.
15. Rice R, Spencer-Dene B, Connor EC etal. Disruption of Fgf10/Fgfr2b-coordinated epithelial-mesenchymal interactions causes cleft palate. J Clin Invest 2004;113:1692-1700.
16. Butali A, Mossey PA, Adeyemo WL etal. Genetic studies in Nigerian population implicate an MSX1 mutation in complex oral facial clefting disorders. Cleft Palate Craniofac J 2011;48:646-653.
17. Chersich MF, Urban MF, Venter FW etal. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006;3:11.
18. Saxen I. Cleft lip and palate in Finland: parental histories, course of pregnancy and selected environmental factors. Int J Epidemiol 1974;3:263-270.
19. Jungmann EM, Mercey D, DeRuiter A etal. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect 2001;77:441-443.
20. Joao EC, Calvet GA, Krauss MR etal. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 2010;53:176-185.
21. Knapp KM, Brogly SB, Muenz DG etal. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012;31:164-170.
22. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf 2005;4:323-335.
23. Brogly SB, Abzug MJ, Watts DH etal. Birth defects among children born to human immunodeficiency virus-infected women, Pediatric AIDS Clinical Trials Protocols 219 and 219C. Pediatr Infect Dis J 2010;29:721-727.
24. Antiretroviral Pregnancy Registry. Interim report, December 2011. 2011. Available from URL: http://www.APRegistry.com/forms/interim_report.pdf.
25. Dorangeon PH, Marx-Chemla C, Quereux C etal. The risks of pyrimethamine-sulfadoxine combination in the prenatal treatment of toxoplasmosis. J Gynecol Obstet Biol Reprod (Paris) 1992;21:549-556.
26. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. N Engl J Med 1995;333:1369-1373.
27. Loffredo LC, Souza JM, Freitas JA, Mossey PA. Oral clefts and vitamin supplementation. Cleft Palate Craniofac J 2001;38:76-83.
28. Boo NY, Arshad AR. A study of cleft lip and palate in neonates born in a large Malaysian maternity hospital over a 2-year period. Singapore Med J 1990;31:59-62.
29. Arribas JR, Pulido F, Miró JM etal. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). AIDS 2002;16:1554-1556.
30. Pulido F, Arribas JR, Miró JM etal. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004;35:343-350.